US 7,456,286 B2
Bicyclic heteroaromatic compounds as kinase inhibitors
Daniel Christopher Brookings, Reading (United Kingdom); Rachel Jane Cubbon, Slough (United Kingdom); Jeremy Martin Davis, Wokingham (United Kingdom); and Barry John Langham, Reading (United Kingdom)
Assigned to UCB Pharma, S.A., Brusseles (Belgium)
Appl. No. 10/529,413
PCT Filed Sep. 30, 2003, PCT No. PCT/GB03/04214
§ 371(c)(1), (2), (4) Date Jun. 23, 2005,
PCT Pub. No. WO2004/031188, PCT Pub. Date Apr. 15, 2004.
Claims priority of application No. 0222743.7 (GB), filed on Oct. 01, 2002.
Prior Publication US 2006/0122212 A1, Jun. 08, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/02 (2006.01); A01N 43/90 (2006.01)
U.S. Cl. 546—113  [514/300] 4 Claims
 
1. A compound of formula (1):

OG Complex Work Unit Drawing
wherein:
the dashed line joining A and C(Ra) is present and represents a bond and A is a —C(Rb)═ group;
Ra and Rb are each hydrogen;
X is a —CH═ group;
Y is a —C(Re)═ group;
Re is hydrogen, —CN, —COR1, —CO2R1, —CONR1aR2a, —S(O)2NR1aR2a, —CONR1a OR2a or —C(O)N(R3a)NR1aR2a;
R1 is methyl, ethyl or trifluoromethyl
R1a and R2a are, independently, a hydrogen atom or methyl group, or together with the nitrogen atom to which they are attached, represent —(CH2)4— or —CH(CH2OH)(CH2)3—;
R3a is a hydrogen atom or C1-6alkyl group;
L is a —CH2—, —CH(CH3)—, —C(O)— or —CH2CH2— group;
n is zero;
Alk1 is an optionally substituted aliphatic or heteroaliphatic chain;
L1 is a covalent bond;
Cy1 is phenyl, methylphenyl, methoxyphenyl, thienyl or indolyl; and
Ar represents phenyl, pyridinyl, thienyl or benzothienyl, any of which groups may be optionally substituted by one or two substituents selected from halogen, cyano, C1-6 alkyl, C1-6 alkoxy and nitro;
or a pharmaceutically acceptable salt or N-oxide thereof.